BNTC vs XOMA
BNTC: Benitec is a clinical-stage gene therapy company developing DNA-directed RNA interference (ddRNAi) treatments delivered via adeno-associated viral vectors to potentially provide "one-shot" cures for genetic diseases. XOMA: A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights across a diversified 120+ asset portfolio spanning oncology, rare disease, and specialty therapeutics.
Side-by-side fundamentals
| Metric | BNTC | XOMA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $11.58 | $40.17 | |
| Market cap as of 2026-08-01 | $402M | $504M | |
| P/E as of 2026-08-01 | n/a | 21.00 | |
| Net margin as of 2026-08-01 | -20671.4% | +69.6% | XOMA higher |
| Gross margin as of 2026-08-01 | +100.0% | +100.0% | Tie |
| Operating margin as of 2026-08-01 | -20714.3% | +61.3% | XOMA higher |
| ROE as of 2026-08-01 | -45.9% | +32.4% | XOMA higher |
| ROA as of 2026-08-01 | -44.0% | +13.1% | XOMA higher |
| Debt / equity as of 2026-08-01 | 0.00 | 0.91 | BNTC lower |
| Revenue growth (YoY) as of 2026-08-01 | n/a | +13.2% | |
| Revenue CAGR (3y) SEC XBRL | -93.0% | +105.3% | XOMA higher |
| Dividend yield as of 2026-08-01 | n/a | +0.8% | |
| Beta as of 2026-08-01 | 0.28 | 0.88 | |
| 1-year return as of 2026-07-27 close | +3.6% | +57.7% | XOMA higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.